These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 36268606)

  • 1. Atopic dermatitis-like graft-versus-host disease treated with dupilumab.
    Larijani M; Zarowin D; Wohlschlaeger A; Perman MJ; Treat JR
    Pediatr Dermatol; 2023 Mar; 40(2):320-322. PubMed ID: 36268606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid response to dupilumab treatment in children with moderate-to-severe atopic dermatitis: A case series.
    Votto M; Delle Cave F; De Filippo M; Marseglia A; Marseglia GL; Brazzelli V; Licari A
    Pediatr Allergy Immunol; 2022 Jan; 33 Suppl 27(Suppl 27):31-33. PubMed ID: 35080304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful response to dupilumab in a refractory case of atopic dermatitis-like chronic cutaneous graft-versus-host disease.
    Tierney E; Evans P; Broderick V; Wynn R; Irvine AD
    Br J Dermatol; 2024 Mar; 190(4):581-583. PubMed ID: 38123149
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment Outcomes Associated With Dupilumab Use in Patients With Atopic Dermatitis: 1-Year Results From the RELIEVE-AD Study.
    Strober B; Mallya UG; Yang M; Ganguli S; Gadkari A; Wang J; Sierka D; Delevry D; Kimball AB
    JAMA Dermatol; 2022 Feb; 158(2):142-150. PubMed ID: 34910086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial.
    Paller AS; Bansal A; Simpson EL; Boguniewicz M; Blauvelt A; Siegfried EC; Guttman-Yassky E; Hultsch T; Chen Z; Mina-Osorio P; Lu Y; Rossi AB; He X; Kamal M; Graham NMH; Pirozzi G; Ruddy M; Eckert L; Gadkari A
    Am J Clin Dermatol; 2020 Feb; 21(1):119-131. PubMed ID: 31823222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2.
    Cork MJ; Eckert L; Simpson EL; Armstrong A; Barbarot S; Puig L; Girolomoni G; de Bruin-Weller M; Wollenberg A; Kataoka Y; Remitz A; Beissert S; Mastey V; Ardeleanu M; Chen Z; Gadkari A; Chao J
    J Dermatolog Treat; 2020 Sep; 31(6):606-614. PubMed ID: 31179791
    [No Abstract]   [Full Text] [Related]  

  • 7. Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
    Beck LA; Deleuran M; Bissonnette R; de Bruin-Weller M; Galus R; Nakahara T; Seo SJ; Khokhar FA; Vakil J; Xiao J; Marco AR; Levit NA; O'Malley JT; Shabbir A
    Am J Clin Dermatol; 2022 May; 23(3):393-408. PubMed ID: 35503163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An updated reappraisal of dupilumab in children and adolescents with moderate-severe atopic dermatitis.
    Ciprandi G; Licari A; Tosca MA; Miraglia Del Giudice M; Belloni Fortina A; Marseglia GL
    Pediatr Allergy Immunol; 2024 Jun; 35(6):e14181. PubMed ID: 38934228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis.
    Silverberg JI; Simpson EL; Boguniewicz M; De Bruin-Weller MS; Foley P; Kataoka Y; Bégo-Le-Bagousse G; Chen Z; Shumel B; Chao J; Rossi AB
    Acta Derm Venereol; 2021 Nov; 101(11):adv00585. PubMed ID: 34618162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial.
    Ständer S; Kwatra SG; Silverberg JI; Simpson EL; Thyssen JP; Yosipovitch G; Zhang F; Cameron MC; Cella RR; Valdez H; DiBonaventura M; Feeney C
    Am J Clin Dermatol; 2023 Jan; 24(1):97-107. PubMed ID: 36512175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
    Blauvelt A; de Bruin-Weller M; Gooderham M; Cather JC; Weisman J; Pariser D; Simpson EL; Papp KA; Hong HC; Rubel D; Foley P; Prens E; Griffiths CEM; Etoh T; Pinto PH; Pujol RM; Szepietowski JC; Ettler K; Kemény L; Zhu X; Akinlade B; Hultsch T; Mastey V; Gadkari A; Eckert L; Amin N; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Shumel B
    Lancet; 2017 Jun; 389(10086):2287-2303. PubMed ID: 28478972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial.
    Paller AS; Siegfried EC; Thaçi D; Wollenberg A; Cork MJ; Arkwright PD; Gooderham M; Beck LA; Boguniewicz M; Sher L; Weisman J; O'Malley JT; Patel N; Hardin M; Graham NMH; Ruddy M; Sun X; Davis JD; Kamal MA; Khokhar FA; Weinreich DM; Yancopoulos GD; Beazley B; Bansal A; Shumel B
    J Am Acad Dermatol; 2020 Nov; 83(5):1282-1293. PubMed ID: 32574587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful Combination of Systemic Agents for the Treatment of Atopic Dermatitis Resistant to Dupilumab Therapy.
    Gori N; Chiricozzi A; Malvaso D; D'Urso DF; Caldarola G; De Simone C; Peris K
    Dermatology; 2021; 237(4):535-541. PubMed ID: 33477153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dupilumab: A review of its use in the treatment of atopic dermatitis.
    Gooderham MJ; Hong HC; Eshtiaghi P; Papp KA
    J Am Acad Dermatol; 2018 Mar; 78(3 Suppl 1):S28-S36. PubMed ID: 29471919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.
    Bieber T; Simpson EL; Silverberg JI; Thaçi D; Paul C; Pink AE; Kataoka Y; Chu CY; DiBonaventura M; Rojo R; Antinew J; Ionita I; Sinclair R; Forman S; Zdybski J; Biswas P; Malhotra B; Zhang F; Valdez H;
    N Engl J Med; 2021 Mar; 384(12):1101-1112. PubMed ID: 33761207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dupilumab for children and adolescents with atopic dermatitis: An Asian perspective.
    Chia SY; Wee LWY; Koh MJA
    Dermatol Ther; 2021 May; 34(3):e14933. PubMed ID: 33751751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safe and effective treatment of atopic dermatitis using dupilumab over 23 months in a patient with HIV.
    Lor M; Villa N; Holland V
    Dermatol Ther; 2020 Nov; 33(6):e14271. PubMed ID: 32882092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS.
    Silverberg JI; Yosipovitch G; Simpson EL; Kim BS; Wu JJ; Eckert L; Guillemin I; Chen Z; Ardeleanu M; Bansal A; Kaur M; Rossi AB; Graham NMH; Patel N; Gadkari A
    J Am Acad Dermatol; 2020 Jun; 82(6):1328-1336. PubMed ID: 32135208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of dupilumab on the disease burden in children and adolescents with atopic dermatitis: A population-based cohort study.
    Tsai SY; Gaffin JM; Hawryluk EB; Ruran HB; Bartnikas LM; Oyoshi MK; Schneider LC; Phipatanakul W; Ma KS
    Allergy; 2024 Oct; 79(10):2748-2758. PubMed ID: 39166365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful Use of Dupilumab in Atopic Dermatitis-Like Graft-Versus-Host Disease: A Case Report.
    Liao Q; Lee CY; Hu Y; Wu S; He Y
    Skin Res Technol; 2024 Oct; 30(10):e70075. PubMed ID: 39366921
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.